Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dingell, Stupak ask firms to remove BPA

This article was originally published in The Tan Sheet

Executive Summary

Michigan Democrats John Dingell, chairman of the House Energy and Commerce Committee, and Oversight and Investigations Subcommittee Chairman Bart Stupak ask infant formula makers Abbott, Mead Johnson, Nestle and PBM to voluntarily remove the chemical bisphenol A from their infant formula packaging. Dingell and Stupak in April asked FDA to reconsider BPA's safety in infant products (1"The Tan Sheet" April 12, 2008, In Brief). "We believe this measure will help protect developing infants and children from the neural, behavioral and developmental risks of BPA" and provide reassurance to concerned parents, the congressmen say in their May 6 letter to the firms. The lawmakers ask the companies to respond in writing to their letter and deliver a response to subcommittee no later than May 20...

You may also be interested in...



FDA Shift On BPA May Tighten Squeeze On Infant Formula Manufacturers

FDA's shift in position regarding the safety of bisphenol A likely will expedite the trend toward BPA-free packaging among infant formula marketers, even though existing science does not demonstrate a proven threat to babies and children

Bisphenol A safe?

Results of National Toxicology Program research prompt Michigan Democrats John Dingell, chairman of the House Energy and Commerce Committee, and Bart Stupak, Oversight and Investigations Subcommittee, to ask FDA to reconsider the safety of the chemical bisphenol A in products intended for use by infants and children. In an April 14 draft brief, the NTP concludes there is "some concern for neural and behavioral effects in fetuses, infants, and children at current human exposures" and "the possibility that bisphenol A may alter human development cannot be dismissed." Stupak says FDA relied on two industry-funded studies to determine the chemical's safety while other authorities "used all available data to reach vastly different conclusions"...

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

Topics

UsernamePublicRestriction

Register

PS101634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel